Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29194337 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| SCHEMBL23420282 | 0.97 | ALDH1A1 (0.37) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| SCHEMBL24760 | 0.84 | — | — | |
| SCHEMBL6523333 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| SCHEMBL31004029 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL31267456 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| Bromide SCHEMBL29640683 | 0.81 | — | — | |
| Water SCHEMBL28721441 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL11149001 | 0.81 | — | — | |
| Phosphine SCHEMBL28328730 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079809-A | Synthesis method of dipeptide linker of antibody coupling degradation agent | — | 2026-05-26 | — | — | CN | claimed |
| CN-122060015-A | Pt (IV) -glycyrrhetinic acid compound and preparation method and application thereof | 重庆大学 | 2026-05-19 | — | — | CN | claimed |
| CN-120058563-A | Preparation method of polypeptide side chain | 杭州中美华东制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119930797-A | Preparation method and application of S-adenosyl homocysteine artificial complete antigen | 珠海科技学院 | 2025-05-06 | — | — | CN | claimed |
| CN-119838022-A | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119118934-A | O-benzo three Azole-tetramethyl Synthesis method of urea tetrafluoroborate | 江苏恒洲化工有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-116143787-B | TP-472 intermediate and preparation method and application thereof | 烟台皓元生物医药科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118812387-A | Sotalol intermediate compounds | 山东新时代药业有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118788281-A | Synthesis device and synthesis method for tetramethyl urea tetrafluoroborate | 江苏恒洲化工有限公司 | 2024-10-18 | — | — | CN | claimed |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | claimed |
| CN-104277097-B | Method for preparing synthetic peptide antigen 2700 of swine O-type foot and mouth disease through solid-phase fragment process | 申联生物医药（上海）股份有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-104277098-B | Method for preparing synthetic peptide antigen 2600 of swine O-type foot and mouth disease through solid-phase fragment process | 申联生物医药（上海）股份有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-104311673-B | Method for preparing pig O-type foot-and-mouth disease synthetic peptide antigen 2800 by using solid-phase fragment method | 申联生物医药（上海）股份有限公司 | 2017-04-12 | — | — | CN | claimed |
| CN-106459169-A | Pharmaceutically relevant aromatic-cationic peptides | 康德生物医疗技术公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106132984-A | Pharmaceutically-related aromatic-cationic peptides | 康德生物医疗技术公司 | 2016-11-16 | — | — | CN | claimed |
| CN-103204867-B | Chiral aminoboronic acid ester and preparation method and its application in bortezomib synthesizes | 成都爱群科技有限公司 | 2016-08-03 | — | — | CN | claimed |
| CN-104418935-A | Preparation method of telaprevir key intermediate | CHENGDU AIQUN TECHNOLOGY CO LTD | 2015-03-18 | — | — | CN | claimed |
| CN-103204867-A | chiral alpha-amino boric acid esters, a preparation method and an application in the synthesis of bortezomib thereof | CHENGDU AIQUN TECHNOLOGY CO LTD | 2013-07-17 | — | — | CN | claimed |
| CN-102781236-A | Amino acid conjugates of quetiapine, methods of making and using the same | KEMPHARM INC | 2012-11-14 | — | — | CN | claimed |
| CN-101141959-B | 2, 5-disubstituted benzophenone derivatives as glycine transporter 1(GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders | HOFFMANN LA ROCHE | 2010-12-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | ALDH1A1 380/4885TSHR 2469/4885NFKB1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.